
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. reported a significant year-over-year gross margin increase of approximately 80 basis points, reaching 79.8% for the second quarter of 2025, which indicates improved operational efficiency. The company achieved a revenue growth of around 23% year-over-year, totaling $46.4 million, driven by a notable increase in surgeon interactions and productivity from sales representatives. Furthermore, the upward revision of the 2025 revenue estimate to $196.5 million reflects the strong performance in Q2 and enhanced sales productivity, underscoring a positive trajectory for the company’s financial performance.
Bears say
The analysis indicates a negative outlook for SI-BONE Inc. primarily due to persistent pricing and procedural challenges within the global spine market, which have resulted in diminished growth rates in the low-single digits. Furthermore, the potential for payors to favor reimbursement for competitive products poses a significant risk to SI-BONE’s market share in the sacroiliac joint fusion market, which could detrimentally impact the company's revenue. Additionally, SI-BONE's EV/sales/growth metric of 0.19x significantly lags behind the median of 0.34x among its small to mid-cap growth peers, underscoring potential concerns regarding valuation and future growth prospects.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares